Lab-on-a-chip: applications in proteomics

Mouradian, Stéphane

doi:10.1016/s1367-5931(01)00280-0

Cited by 95 publications

(39 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Herein we describe the application on human tumor cells of an approach aimed at developing entire laboratories on a single substrate, the so-called "lab-on-a-chip" (Chovan and Guttman, 2002;Kricka, 2001;Mouradian, 2002), using active substrates based on microelectronic technology and integrating the biochip in the substrate circuits that could carry out actuating and sensing functions.…”

Section: Introductionmentioning

confidence: 99%

Levitation and movement of human tumor cells using a printed circuit board device based on software‐controlled dielectrophoresis

Altomare¹,

Borgatti²,

Medoro³

et al. 2003

Biotech & Bioengineering

View full text Add to dashboard Cite

In this study we describe an original, efficient, and innovative printed circuit board (PCB) device able to generate dielectrophoresis-based, software-controlled cages that can be moved to any place inside a microchamber. Depending on their dielectrophoretic properties, eukaryotic cells can be "entrapped" in cages and moved under software control. The main conclusion gathered from the experimental data reported is that the PCB device based on dielectrophoresis permits levitation and movement of different tumor cells at different dielectrophoresis conditions. The results presented herein are therefore the basis for experiments aimed at forced interactions or separation of eukaryotic cells using "lab-on-a-chip." In fact, because many cages can be controlled at the same time, and two or more cages can be forced to share the same or a different location, it is possible, in principle, either to bring in contact cells of a differing histotype or to separate them.

show abstract

Section: Introductionmentioning

confidence: 99%

Levitation and movement of human tumor cells using a printed circuit board device based on software‐controlled dielectrophoresis

Altomare¹,

Borgatti²,

Medoro³

et al. 2003

Biotech & Bioengineering

View full text Add to dashboard Cite

show abstract

“…Miniaturization of those steps might help to improve sensitivity. In that sense, microfluidic systems or chips have the ability to integrate a whole analytical strategy on a single chip, and thus require a minimum of sample and reduce greatly any sample loss (lab-on-chip technology; Figeys & Pinto, 2001;Figeys, 2002;Mouradian, 2002). Cancer research and medical science should greatly benefit from those advances in technologies whose aim is to increase sensitivity, reduce sample requirement, increase throughput, or allow PTM and quantification studies.…”

Section: Discussionmentioning

confidence: 99%

The potentials of MS‐based subproteomic approaches in medical science: The case of lysosomes and breast cancer

Journet

Ferro

2004

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Because of the great number of women who are diagnosed with breast cancer each year, and though this disease presents the lowest mortality rate among cancers, breast cancer remains a major public health problem. As for any cancer, the tumorigenic and metastatic processes are still hardly understood, and the biochemical markers that allow either a precise monitoring of the disease or the classification of the numerous forms of breast cancer remain too scarce. Therefore, great hopes are put on the development of high-throughput genomic and proteomic technologies. Such comprehensive techniques should help in understanding the processes and in defining steps of the disease by depicting specific genes or protein profiles. Because techniques dedicated to the current proteomic challenges are continuously improving, the probability of the discovery of new potential protein biomarkers is rapidly increasing. In addition, the identification of such markers should be eased by lowering the sample complexity; e.g., by sample fractionation, either according to specific physico-chemical properties of the proteins, or by focusing on definite subcellular compartments. In particular, proteins of the lysosomal compartment have been shown to be prone to alterations in their localization, expression, or post-translational modifications (PTMs) during the cancer process. Some of them, such as the aspartic protease cathepsin D (CatD), have even been proven as participating actively in the disease progression. The present review aims at giving an overview of the implication of the lysosome in breast cancer, and at showing how subproteomics and the constantly refining MS-based proteomic techniques may help in making breast cancer research progress, and thus, hopefully, in improving disease treatment.

show abstract

“…With advances in nanotechnologies and microfluidics, significant progress has been made in integrating conventional assays into a miniaturized lab-on-a-chip [5][6][7]. For example, on-chip technologies have been developed for the gold standard methods of protein profiling such as mass spectrometry (MS) [8−11], enzyme-linked immunosorbent assay (ELISA) [12−15], Western blotting (WB) [16−19] and fluorescence detection [20,21].…”

Section: Overview Of Devices For Protein Diagnosticsmentioning

confidence: 99%